Schering Corporation

Merck Sharp + Dohme Corp.

Other

Pharmacopeia Drug Discovery, Inc.

Pharmacopeia Inc.

De-Yi Yang

Joseph A Kozlowski

Wensheng Yu

Michael K C Wong

Ling Tong

Brian J Lavey

Guowei Zhou

Bandarpalle B Shankar

Seong Heon Kim

Dansu Li

Neng-Yang Shih

Lei Chen

Kristin E Rosner

M Arshad Siddiqui

Janeta Popovici-Muller

Vinay M Girijavallabhan

Razia Rizvi

Chaoyang Dai

Vincent Stewart Madison

Zhuyan Guo

Peter Orth

Robert Feltz

Judson E Richard

Aneta Maria Kosinski

Luke Fire

Aneta M Micula

Michael W Miller

Steven L Colletti

Duane E DeMong

Umar Faruk Mansoor

Anilkumar G Nair

Liping Yang

Seong-Heon Kim

William J Greenlee

Andrew William Stamford

Tesfaye Biftu

Ravi P Nargund

Craig Alan Coburn

Michael P Dwyer

Qun Dang

Hubert B Josien

Stuart B Rosenblum

Bin Hu

Dong Xiao

Xing Dai

Cheng Zhu

Purakkattle J Biju

Helen Y Chen

Brian F McGuinness

Yan Guo

Kartik M Keertikar

Christopher W Plummer

Qingbei Zeng

Dahai Wang

Gopinadhan N Anilkumar

Deyou Sha

Bin Zhong

Nam Fung Kar

Jae-Hun Kim

Jinglai Hao

Pawan Dhondi

Candido Gude

Lisa Guise Zawacki

Aneta Maria Kosinzki

Doublas W Hobbs

Kristen E Rosner

Shankar B Bandarpalle

Duane Eugene Demong

Michael Miller

Razia K Rizvi

Pawan K Dhondi

Michael KC Wong

Aneta S Micula

Robert Schering-Plough Corporation Feltz

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. 

Antidiabetic bicyclic compounds

The present invention relates to novel Heterocycle-Substituted Tetracyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, A', RRand Rare as defined herein. The present invention also relates to compositions comprising at least one Heterocycle-Substituted Tetracyclic Compound, and methods of using the Heterocycle-Substituted Tetracyclic Compounds for treating or preventing HCV infection in a patient. 

Heterocycle-substituted tetracyclic compounds and methods of use thereof for the treatment of viral diseases

Antidiabetic tricyclic compounds

This invention relates to compounds of the Formula (I) as described herein, or a pharmaceutically acceptable salt, solvate or ester thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof. 

Compounds for the treatment of inflammatory disorders

This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof. 

This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF&#x2014;or combinations thereof. 

This invention relates to compounds of the Formula (I)-(IX):, as defined herein, or a pharmaceutically acceptable salt, solvate or ester thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF-&#x3b1; combinations thereof. 

Compounds for the treatment of inflammatory diseases

The present invention relates to compounds of the general formula: (I) wherein ring A, ring B, R, R, Z, L, and Lare selected independently of each other and are as defined herein, to compositions comprising the compounds, and to methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto. 

Spiro-imidazolone derivatives as glucagon receptor antagonists

This invention relates to compounds of the Formula (I): 

The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts or solvates of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: and the pharmaceutically acceptable salts, solvates or esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

Heteroaryl substituted pyrazinyl-piperazine-piperidines with CXCR3 antagonist activity

Growing community of inventors

Morris Plains, NJ, United States of America

De-Yi Yang